skin reaction to tirzepatide injection Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions Zepbound Injection Site Reaction: Causes

FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression [PMID: 40019747] Laboratory literature summary: FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression

For patients with severe obesity (BMI 40 or 35 with obesity-related complications), referral for evaluation of bariatric surgery may be appropriate according to American Society for Metabolic and Bariatric Surgery guidelines

Choosing between GLP-1s and deciding how dosing should be approached is not something most people should guess at

For example, people with type 2 diabetes and kidney or gallbladder issues may need extra monitoring when taking semaglutide